b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">28389932</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>06</Month>\n            <Day>18</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>12</Month>\n            <Day>02</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1435-5604</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>36</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>May</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of bone and mineral metabolism</Title>\n                <ISOAbbreviation>J. Bone Miner. Metab.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Monthly oral ibandronate 100\xc2\xa0mg is as effective as monthly intravenous ibandronate 1\xc2\xa0mg in patients with various pathologies in the MOVEST study.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>336-343</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00774-017-0839-2</ELocationID>\n            <Abstract>\n                <AbstractText>The non-inferiority of oral ibandronate 100\xc2\xa0mg to intravenous (i.v.) ibandronate 1\xc2\xa0mg in increasing lumbar spine (LS) bone mineral density (BMD) after 12\xc2\xa0months of treatment was demonstrated in the randomized, phase III MOVEST study. We conducted subgroup analyses in the per-protocol set of the study (n\xc2\xa0=\xc2\xa0183 oral ibandronate; n\xc2\xa0=\xc2\xa0189 i.v. ibandronate). In patients with LS BMD T score \xe2\x89\xa5 -3.0 or &lt; -3.0 at screening, LS BMD gains from baseline were 4.42 and 5.79%, respectively, with oral ibandronate, and 4.60 and 5.83%, respectively, with i.v. ibandronate. LS BMD gains in patients with or without prevalent vertebral fractures were 5.21 and 5.23%, respectively, with oral ibandronate, and 5.01 and 5.49%, respectively, with i.v. ibandronate. In patients aged &lt;75 or \xe2\x89\xa575\xc2\xa0years, LS BMD gains were 5.46 and 4.51%, respectively, with oral ibandronate, and 5.25 and 5.77%, respectively, with i.v. ibandronate. LS BMD gains in patients with baseline 25-hydroxyvitamin D levels \xe2\x89\xa520 or &lt;20\xc2\xa0ng/mL were 5.35 and 4.76%, respectively, with oral ibandronate, and 5.05 and 6.57%, respectively, with i.v. ibandronate. Similar results were obtained in patients with or without prior bisphosphonate (BP) treatment, and in those receiving osteoporosis drug treatment other than BPs. In conclusion, oral ibandronate 100\xc2\xa0mg demonstrated comparable BMD gains with monthly i.v. ibandronate, and thus shows high utility in the lifestyle and disease conditions associated with osteoporosis in Japanese patients.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Hagino</LastName>\n                    <ForeName>Hiroshi</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Faculty of Medicine, School of Health Science and Rehabilitation Division, Tottori University, Tottori, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ito</LastName>\n                    <ForeName>Masako</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Center for Diversity and Inclusion, Nagasaki University, Nagasaki, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hashimoto</LastName>\n                    <ForeName>Junko</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. hashimotojnk@chugai-pharm.co.jp.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yamamoto</LastName>\n                    <ForeName>Masao</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Endo</LastName>\n                    <ForeName>Koichi</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Katsumata</LastName>\n                    <ForeName>Kyoko</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Asao</LastName>\n                    <ForeName>Yoshihiro</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Matsumoto</LastName>\n                    <ForeName>Rumiko</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Taisho Pharmaceutical Co., Ltd., Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nakano</LastName>\n                    <ForeName>Tetsuo</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Tamana Central Hospital, Kumamoto, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mizunuma</LastName>\n                    <ForeName>Hideki</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Fukushima Medical University, Fukushima, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nakamura</LastName>\n                    <ForeName>Toshitaka</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Aoba Hospital, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>04</Month>\n                <Day>07</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Japan</Country>\n            <MedlineTA>J Bone Miner Metab</MedlineTA>\n            <NlmUniqueID>9436705</NlmUniqueID>\n            <ISSNLinking>0914-8779</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>UMD7G2653W</RegistryNumber>\n                <NameOfSubstance UI="D000077557">Ibandronic Acid</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015519" MajorTopicYN="N">Bone Density</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004164" MajorTopicYN="N">Diphosphonates</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077557" MajorTopicYN="N">Ibandronic Acid</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008159" MajorTopicYN="N">Lumbar Vertebrae</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010024" MajorTopicYN="N">Osteoporosis</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Ibandronate</Keyword>\n            <Keyword MajorTopicYN="N">Intravenous</Keyword>\n            <Keyword MajorTopicYN="N">MOVEST study</Keyword>\n            <Keyword MajorTopicYN="N">Oral</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2016</Year>\n                <Month>10</Month>\n                <Day>24</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2017</Year>\n                <Month>03</Month>\n                <Day>29</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>4</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>6</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>4</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">28389932</ArticleId>\n            <ArticleId IdType="doi">10.1007/s00774-017-0839-2</ArticleId>\n            <ArticleId IdType="pii">10.1007/s00774-017-0839-2</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Osteoporos Int. 2012 Jun;23 (6):1747-56</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21953471</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Calcif Tissue Int. 2009 Nov;85(5):398-404</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19795092</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Joint Bone Spine. 2008 May;75(3):303-10</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18069036</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):139-47</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25476995</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Calcif Tissue Int. 2013 Aug;93(2):137-46</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23644930</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Rheumatol. 2008 Mar;35(3):488-97</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18260172</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Bone Miner Metab. 2001;19(6):331-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11685647</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Calcium. 2016 Feb;26(2):251-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26813505</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Osteoporos Int. 2014 Jan;25(1):349-57</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24136103</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Calcif Tissue Int. 2010 Oct;87(4):305-13</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20737140</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Rheum Dis. 2006 May;65(5):654-61</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16339289</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Bone. 2009 Mar;44(3):423-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19049913</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Bone Miner Metab. 2017 Jan;35(1):58-64</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26614597</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Bone Miner Metab. 2016 Nov;34(6):678-684</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26462480</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Osteoporos Int. 2009 Feb;20(2):291-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18663402</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Calcif Tissue Int. 2014 Dec;95(6):557-63</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25377907</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Med Res Opin. 2005 Dec;21(12 ):1895-903</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16368038</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Osteoporos Int. 2012 Oct;23(10):2479-87</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22237813</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Med Res Opin. 2008 Jan;24(1):237-45</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18047776</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Osteoporos Int. 2015 Nov;26(11):2685-93</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26001561</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Osteoporos Int. 2016 May;27(5):1777-84</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26733376</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Osteoporos Int. 2012 Jun;23 (6):1769-78</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21975558</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'